The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Immunomodulation with pomalidomide in AML and high-risk MDS
Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
